At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of Blood Flow and Vascular Function on Exercise Capacity in Cystic Fibrosis
In Brief
A Phase 2 clinical trial evaluating Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks), and 1 other intervention for Cystic Fibrosis. Completed, enrolled 19 participants across 1 site.
Detailed Summary
Cystic fibrosis (CF) has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections. However, the physiological mechanisms for this reduced exercise capacity are unknown. The investigators laboratory recently published the first evidence of systemic vascular dysfunction in patients with CF. Therefore, it is reasonable to suspect that the blood vessels are involved with exercise intolerance in CF. This study will look at how 1) blood flow and 2) artery function contribute to exercise capacity in CF.
Study Details
Timeline
Interventions
Vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)
Vascular function will be assessed 4 weeks following 20 mg three times per day (TID) of sildenafil for four weeks
Sugar pill designed to mimic the sildenafil treatment